Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Mycamine
Micafungin is an antifungal drug belonging to the echinocandin class. It works by inhibiting the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall. This leads to cell wall instability and ultimately fungal cell death. Micafungin is effective against a range of Candida species, including those resistant to azoles and fluconazole, as well as Aspergillus species.
For the treatment of candidemia, acute disseminated candidiasis, Candida esophagitis, and prophylaxis of Candida infections in hematopoietic stem cell transplant recipients.
Outcome:
Increased risk of siponimod toxicity
Mechanism:
Micafungin can inhibit CYP3A4, increasing siponimod levels.
Outcome:
Increased risk of nephrotoxicity
Mechanism:
Additive nephrotoxic effects.
Outcome:
No clinically significant interaction expected
Mechanism:
Although both drugs are metabolized by CYP enzymes, no significant interaction is usually observed.
Most likely new formulation: Liposomal micafungin for improved tissue penetration and reduced toxicity (2026, 65% confidence)
Based on current usage trends and clinical trial data, there is a high (80%) likelihood of micafungin maintaining its approved status for the treatment of invasive fungal infections in the next 5 years.
Antifungal, Echinocandin
Echinocandin